Loading
RGCC researchers separated a very small set of colorectal cancer and healthy blood samples using gene-expression clustering. The study was exploratory and does not validate multi-cancer screening in people without symptoms.
RGCC researchers measured expression of more than 50 genes in peripheral blood mononuclear cells and commercial gastrointestinal cancer cell lines. The human normal-versus-cancer analysis contained four healthy donors and six people with colorectal cancer. Additional comparisons used nine colorectal patient samples and commercial cell lines.
The clustering methods separated the small groups used to develop and illustrate the approach. There was no independent prospective screening cohort, prespecified population threshold, diagnostic work-up, stage-specific performance analysis or clinical-outcome endpoint. RGCC links this study from its Onco-D-Clare page, but the study does not validate a pan-cancer screening test or a population accuracy claim.
The paper is early proof of concept for a gene-expression method. It cannot establish screening sensitivity, specificity, tissue of origin, mortality reduction or clinical utility for Onco-D-Clare.
Shares RGCC International, Colorectal cancer and the tag rgcc.
Shares RGCC International and the tag rgcc.
Shares RGCC International, Colorectal cancer.
Shares Multi-cancer early detection (MCED), Colorectal cancer.
Shares Colorectal cancer and the tag screening.
Shares Colorectal cancer and the tag screening.
Shares Colorectal cancer and the tag screening.
Shares Multi-cancer early detection (MCED) and the tag screening.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/